Sunshine Biopharma Inc (NASDAQ: SBFM) closed the day trading at $0.06 down -0.71% from the previous closing price of $0.06. In other words, the price has decreased by -$0.0004 from its previous closing price. On the day, 3444127 shares were traded.
Ratios:
For a better understanding of SBFM, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.11 and its Current Ratio is at 5.00. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 08 when Slilaty Steve N. bought 20,000 shares for $0.10 per share. The transaction valued at 2,000 led to the insider holds 30,000 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SBFM now has a Market Capitalization of 3.06M and an Enterprise Value of -15.11M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.15 while its Price-to-Book (P/B) ratio in mrq is 0.07. Its current Enterprise Value per Revenue stands at -0.74 whereas that against EBITDA is 0.58.
Stock Price History:
Over the past 52 weeks, SBFM has reached a high of $1.40, while it has fallen to a 52-week low of $0.05. The 50-Day Moving Average of the stock is 0.2115, while the 200-Day Moving Average is calculated to be 0.3716.
Shares Statistics:
Over the past 3-months, SBFM traded about 1.92M shares per day on average, while over the past 10 days, SBFM traded about 10.89M shares per day. A total of 54.45M shares are outstanding, with a floating share count of 45.73M. Insiders hold about 16.02% of the company’s shares, while institutions hold 21.60% stake in the company. Shares short for SBFM as of Feb 15, 2024 were 602.57k with a Short Ratio of 0.31, compared to 112.93k on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.11% and a Short% of Float of 1.20%.
Earnings Estimates
Current recommendations for the stock of the company come from 1 analysts. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$0.16 and -$0.16 for the fiscal current year, implying an average EPS of -$0.16. EPS for the following year is $0.09, with 1 analysts recommending between $0.09 and $0.09.
Revenue Estimates
Based on 1 analysts’ estimates, the company’s revenue will be $44.4M in the next fiscal year. The high estimate is $44.4M and the low estimate is $44.4M. The average revenue growth estimate for next year is up 97.20% from the average revenue estimate for this year.
